Review of frovatriptan in the treatment of migraine

Leslie Kelman, Leslie Kelman

Abstract

Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine.

Keywords: frovatriptan triptans; migaine; treatment.

References

    1. Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005;62:1270–5. 34.
    1. Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006;27(Suppl 2):S193–7.
    1. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001;357:1016–17.
    1. Brandes JL, Smith T, Diamond M, et al. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache. 2007;47:886–94.
    1. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002;8:136–42.
    1. Brown AM, Ho M, Thomas DR, et al. Comparison of functional effects of frovatriptan (VML 251), sumatriptan, and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors [abstract] Headache. 1998;38:376.
    1. Brown AM, Parsons AA, Raval P, et al. SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors [abstract] Br J Pharmacol. 1996;119(Suppl):110P.
    1. Buchan P. The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent selective 5-HT1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers [abstract] Headache. 1998;38:376.
    1. Buchan P, Keywood C, Ward C. Pharmacokinetics of Frovatriptan (VML 251/SB 209509) in healthy young and elderly male and female subjects [abstract] Cephalalgia. 1998;18:410.
    1. Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug-drug interactions. Headache. 2002;42(Suppl 2):S63–73.
    1. Buchan P, Ward C, Zeig S. Frovatriptan pharmacokinetics are unaffected during a migraine attack [abstract] Cephalalgia. 1999;19:365.
    1. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26.
    1. Cady R, Elkind A, Goldstein J, et al. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465–72.
    1. Cohen AF, van der Post J, Sacks, et al. Pharmacokinetics of frovatriptan in patients with renal impairment [abstract] Cephalalgia. 1999;19:365.
    1. Cushing DJ, Zgombick JM, Nelson DL, et al. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J Pharmacol Exp Ther. 1996;277:1560–6.
    1. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet. 1988;11:1309–11.
    1. Ebersberger A, Schaible H-G, Averbeck B, et al. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol. 2001;41:7–13.
    1. Elkind AH, Satin LZ, Nila A, et al. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache. 2004;44:403–10.
    1. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–8.
    1. Géraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376–88.
    1. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42(Suppl 2):S93–9.
    1. Goadsby PJ. Migraine, aura and cortical spreading depression: why are we still talking about it? Ann Neurol. 2001;49:4–6.
    1. Goadsby PJ. Migraine pathophysiology. Headache. 2005;45(Suppl 1):S14–24.
    1. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–6.
    1. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat. 1997;190:367–75.
    1. Goadsby PJ, Hoskin KL, Knight YE. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997a;73:23–8.
    1. Goadsby PJ, Hoskin KL, Knight YE. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997b;73:23–8.
    1. Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ. 1996;312:1279–83.
    1. Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat. 1999;194:579–88.
    1. Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache. 2007;47(Suppl 1):S10–9.
    1. Humphrey PP, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988;94:1123–32.
    1. Ingvardsen BK, Laursen H, Olsen UB, et al. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following spreading depression. Pain. 1997a;72:407–15.
    1. Ingvardsen BK, Laursen H, Olsen UB, et al. Comment on Ingvardsen et al. Pain. 1997b;72:407–15. Reply to Moskowitz et al. Pain, 1998; 76: 266–7.
    1. Joutel A, Ducros A, Vahedi K, et al. Genetic heterogeneity of familial hemiplegic migraine. Am J Hum Genet. 1994;55:1166–72.
    1. Kaube H, Keay KA, Hoskin KL, et al. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 1993;629:95–102. 40.
    1. Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:865–72.
    1. Knight YE, Bartsch T, Kaube H, et al. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci. 2002;22:RC213.
    1. Knight YE, Goadsby PJ. The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? Neurosci. 2001;106:793–800.
    1. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF) J Headache Pain. 2005;6:429–40.
    1. Lipton RB. Disability assessment as a basis for stratified care. Cephalalgia. 1998;18(Suppl 22):40–43.
    1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.
    1. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5-HT1D- and 5-HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia. 1997;17:833–842.
    1. Lucas C. Strategies to improve migraine treatment results. Drugs. 2006;66(Suppl 3):9–16.
    1. MacGregor EA, Keywood C. Frovatriptan is effective in menstrually associated migraine. Cephalalgia. 2000;20:345.
    1. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15(Suppl 3):28–35.
    1. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007a;27:414–21.
    1. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007b;47:1037–49.
    1. Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127:220–30.
    1. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci. 1987;7:4129–36.
    1. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin. 1990;8:801–15.
    1. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307–11.
    1. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993;6(Suppl 3):S16–20.
    1. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci. 1993;13:1167–77.
    1. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307–9.
    1. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;413:248–56.
    1. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience. 1992;49:669–80.
    1. Rapoport A, Ryan R, Goldstein J, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002;42(Suppl 2):S74–83.
    1. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations. How to match patients and products. CNS Drugs. 2003;17:431–47.
    1. Russell MB, Iselius L, Olesen J. Investigation of the inheritance of migraine by complex segregation analysis. Hum Genet. 1995;96:726–30.
    1. Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(Suppl 2):S84–92.
    1. Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia. 2002;22:680–5.
    1. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–62.
    1. Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;27:261–9.
    1. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. 2. London, UK: Martin Dunitz; 2002.
    1. Stewart M, Napier CM, Katugampola SD, et al. The binding affinity and functional activity of eletriptan and other 5-HT1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptors [abstract] Br J Pharmacol. 1999;127:93P.
    1. Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019–26.
    1. Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131–6.
    1. Ulrich V, Gervil M, Kyvik KO, et al. Evidence of a genetic factor in migraine with aura: a population based Danish twin study. Ann Neurol. 1999;45:242–6.
    1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995a;1:658–60.
    1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995b;1:658–60.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner